Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 20, 2023

BUY
$36.54 - $54.26 $251,614 - $373,634
6,886 Added 103.74%
13,524 $502,000
Q4 2022

Jan 27, 2023

BUY
$41.27 - $98.62 $273,950 - $654,639
6,638 New
6,638 $0

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Trellus Management Company, LLC Portfolio

Follow Trellus Management Company, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trellus Management Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Trellus Management Company, LLC with notifications on news.